Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Noninvasive radiofrequency fields and targeted gold nanoparticles effective in controlling pancreatic tumors

Kanzius Cancer Research Foundation announces research conducted in the Kanzius/Curley Lab at The University of Texas M.D. Anderson Cancer Center has been published in the December 2010 issue of the American Association of Cancer Research's Clinical Cancer Research journal.

14 Jan 2011

Gut bacteria may play a role in weight loss and gastrointestinal problems: New research

If you are looking to lose weight in the coming year, you may need help from an unexpected place: the bacteria in your gut. That's because scientists have discovered that the bacteria living in your intestines may play a far more significant role in weight loss and gastrointestinal problems than ever imagined.

14 Jan 2011

Cataloguing microbes in gut could lead to cause of necrotizing enterocolitis

Scientists have for the first time sequenced and reconstructed the genomes of most of the microbes in the gut of a premature newborn and documented how the microbe populations changed over time.

14 Jan 2011

Research study to develop rapid, inexpensive blood screening test for early diagnosis of pancreatic cancer

A clinical research study to develop a rapid and inexpensive blood screening test for the early diagnosis of pancreatic cancer has been launched by Henry Ford Health System and the Barbara Ann Karmanos Cancer Institute.

14 Jan 2011

FDA approves Cumberland's Acetadote Injection

Cumberland Pharmaceuticals today announced that it has received approval from the U.S. Food and Drug Administration for a new formulation of Acetadote Injection, the Company's product used to treat acetaminophen poisoning.

13 Jan 2011

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

MedImmune, the global biologics unit of AstraZeneca PLC and Micromet, today announced the initiation of a Phase 1 trial of MEDI-565 in patients with advanced gastrointestinal cancers. MEDI-565 is a BiTE antibody designed to direct a patient's T cells, the body's most potent killer cells, against cancer cells that express carcinoembryonic antigen.

13 Jan 2011

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

GlaxoSmithKline and ChemoCentryx, announced today that the first patient with Crohn's disease has initiated treatment in the initial pivotal induction study comparing Traficet-EN, now designated GSK1605786 ('786), to placebo.

12 Jan 2011

Salix and CCA offer Colonoscopy For Dummies

Salix Pharmaceuticals, Ltd., in partnership with the Colon Cancer Alliance (CCA), is proud to announce the availability of Colonoscopy For Dummies.

12 Jan 2011

Physicians who completed internal medicine training lack primary care knowledge: Study

Doctors who have completed training in internal medicine are in general poorly prepared for jobs as primary care physicians, most notably lacking the knowledge to best care for patients with chronic conditions such as diabetes, hypertension and high cholesterol, new Johns Hopkins research suggests.

12 Jan 2011

SCRI to lead clinical development of AstraZeneca's novel targeted oncology compound

AstraZeneca and Sarah Cannon Research Institute (SCRI), an international leader in advancing therapies for cancer patients through clinical research, today announced that SCRI will lead the clinical development of a novel targeted oncology compound from AstraZeneca.

12 Jan 2011

Floods may become a healthcare challenge, warns the AMA

The Australian Medical Association (AMA) has issued warnings to the Queensland health authorities to prepare for the rise of illnesses and injuries caused by the floods.

10 Jan 2011

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to treat chronic idiopathic constipation patients, planned to begin in the second quarter of 2011, has been designed as a Phase II/III trial.

7 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

Study finds combined treatments safe and effective for severe acute pancreatitis

The use of combined treatments for severe acute pancreatitis is safe and effective in managing the disease, resulting in shorter hospitalizations and fewer radiological procedures than standard therapy, according to a study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. In a related study, doctors found that patients with infected pancreatic necrosis were able to avoid surgery through primary conservative treatment, which is in-patient medical treatment.

7 Jan 2011

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Altheus Therapeutics, announced that it has completed a two dose, double-blind, active-controlled Phase I clinical trial of the safety and tolerability of Zoenasa Rectal Suspension in adult patients with left-sided, or distal, ulcerative colitis.

6 Jan 2011

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Colorectal cancer (CRC) is the third most common cancer in men and women in the USA, with a new diagnosis made every 3.5 minutes and an associated death every 9 minutes.

6 Jan 2011

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

6 Jan 2011

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Salix Pharmaceuticals, Ltd. today announced the New England Journal of Medicine has published results from TARGET 1 and TARGET 2, the Company's two pivotal Phase 3 efficacy and safety studies of XIFAXAN (rifaximin) 550 mg tablets for the treatment of Irritable Bowel Syndrome without constipation, or Non-C IBS.

6 Jan 2011

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

A ground-breaking antibiotic therapy developed at Cedars-Sinai Medical Center is the first potential drug treatment to provide irritable bowel syndrome patients with long-lasting relief of their symptoms even after they stop taking the medication, according to a study published in the Jan. 6 issue of the New England Journal of Medicine.

6 Jan 2011

FDA grants marketing clearance to Crospon's EndoFLIP product

Crospon, an Irish medical device developer based in Galway, has announced that the Company has received clearance from the US Food and Drugs Administration to market a new imaging catheter for the measurement of sleeves created during bariatric surgery.

6 Jan 2011

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Noninvasive radiofrequency fields and targeted gold nanoparticles effective in controlling pancreatic tumors

Gut bacteria may play a role in weight loss and gastrointestinal problems: New research

Cataloguing microbes in gut could lead to cause of necrotizing enterocolitis

Research study to develop rapid, inexpensive blood screening test for early diagnosis of pancreatic cancer

FDA approves Cumberland's Acetadote Injection

Micromet, MedImmune initiate MT111 Phase 1 trial in patients with advanced gastrointestinal cancer

GSK, ChemoCentryx initiate '786 Phase III clinical trial for Crohn's disease

Salix and CCA offer Colonoscopy For Dummies

Physicians who completed internal medicine training lack primary care knowledge: Study

SCRI to lead clinical development of AstraZeneca's novel targeted oncology compound

Floods may become a healthcare challenge, warns the AMA

Synergy's plecanatide Phase II/III trial to begin in second quarter 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Study finds combined treatments safe and effective for severe acute pancreatitis

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Choosing between EGFR therapeutic options in metastatic colorectal cancer

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Study: Antibiotics can provide long-lasting relief to patients with irritable bowel syndrome

FDA grants marketing clearance to Crospon's EndoFLIP product

Microbiology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Microbiology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in